Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1997-04-08
2001-04-10
Fitzgerald, David L. (Department: 1646)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S325000, C435S069100, C435S069500, C435S252300, C435S252330, C530S324000, C530S351000, C536S023510
Reexamination Certificate
active
06214584
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a novel polypeptide which induces the interferon-&ggr; (hereinafter abbreviated as “IFN-&ggr;”) production by immunocompetent cells.
2. Description of the Prior Art
It has been said that IFN-&ggr; is a protein which has antiviral-, antioncotic- and immunoregulatory-activities, and is produced by immunocompetent cells stimulated with antigens or mitogens. Because of these biological activities, IFN-&ggr; has been expected for use as an antitumor agent from the beginning of the finding, and studied energetically on clinical trials as a therapeutic agent for malignant tumors in general including brain tumors. IFN-&ggr; preparations now commercially available are roughly classified into 2 groups, i.e. natural IFN-&ggr;s produced by immunocompetent cells and recombinant IFN-&ggr;s produced by transformants prepared by introducing into microorganisms of the species
Escherichia coli
DNAs which encode the natural IFN-&ggr;s. In the above clinical trials, either of these IFN-&ggr;s is administered to patients as an “exogenous IFN-&ggr;”.
Among these IFN-&ggr;s, the natural IFN-&ggr;s are usually produced by culturing established immunocompetent cells in nutrient culture media supplemented with IFN-&ggr; inducers to form the IFN-&ggr;s, and purifying the IFN-&ggr;s. It is known that the type of IFN-&ggr; inducers greatly influence on the IFN-&ggr; production yield, the facilitation of the IFN-&ggr; purification, and the safeness of the final products. Generally, mitogens such as concanavalin A (Con A),
Lens culinaris, Phytolacca americana,
endotoxin and lipopolysaccharide are used. These mitogens, however, have problems of their molecular- and quality varieties depending on their origins and purification methods, as well as difficulty of yielding in a desired amount and in a constant IFN-&ggr; inducibility. In addition, most of these mitogens induce unfavorable side effects when administered to living bodies, and some of them even show toxicity, so that it is substantially difficult to induce the IFN-&ggr; production by directly administering such mitogens to living bodies.
SUMMARY OF THE INVENTION
In view of the foregoing, the object of the present invention is to provide a novel polypeptide which induces the IFN-&ggr; production by immunocompetent cells.
It is another object of the present invention to provide a DNA encoding the polypeptide.
It is further object of the present invention to provide a replicable recombinant DNA which contains the DNA and a self-replicable vector.
It is yet another object of the present invention to provide a transformant obtainable by introducing the recombinant DNA into an appropriate host.
It is another object of the present invention to provide a process for preparing the polypeptide by using the transformant.
[Means to Attain the Object]
The first object of the present invention is attained by a polypeptide which has the amino acid sequence in SEQ ID NO:1 or a homologous amino acid sequence thereunto.
The second object of the present invention is attained by a DNA which encodes the polypeptide.
The third object of the present invention is attained by a replicable recombinant DNA which contains the DNA and a self-replicable vector.
The fourth object of the present invention is attained by a transformant obtainable by introducing the replicable recombinant DNA into an appropriate host.
The fifth object of the present invention is attained by a process for preparing the protein comprising introducing the recombinant DNA into a host, culturing the transformant in a nutrient culture medium, and collecting the formed protein from the resultant culture.
REFERENCES:
patent: 0692536 (1996-01-01), None
patent: 9205256 (1992-04-01), None
patent: 97/24441 (1997-07-01), None
Okamura et al., “Cloning of a new cytokine that induces IFN- production by T cells”,Letters To Naturevol. 378, pp. 88-91, (1995).
XP-002024314, (1993).
Japan Abstract 05279376, Oct. 26, 1993.
H. Okamura et al, “Cloning of a new cytokine that induce IFN-gamma production by T cells”, Nature, vol. 378, No. 6552, pp. 88-92.
Sambrook, J. et al., “Molecular Cloning, A Laboratory Manual.” 2nd Edition, pp. xi-xxxviii (1989).
Muramatsu, Masami., “Laboratory Manual for Genetic Engineering.” pp. v-ix, (1988).
Kurimoto Masashi
Okamura Haruki
Tanimoto Tadao
Torigoe Kakuji
Ushio Shimpei
Andres Janet L.
Browdy and Neimark
Fitzgerald David L.
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
LandOfFree
Human Interferon-&ggr;inducing factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human Interferon-&ggr;inducing factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human Interferon-&ggr;inducing factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2521850